Unknown

Dataset Information

0

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.


ABSTRACT: Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-19, little is known about their mechanism(s) of action or effective dosing windows. We report the generation and development of SC31, a potent SARS-CoV-2 neutralizing antibody, isolated from a convalescent patient. Antibody-mediated neutralization occurs via an epitope within the receptor-binding domain of the SARS-CoV-2 Spike protein. SC31 exhibited potent anti-SARS-CoV-2 activities in multiple animal models. In SARS-CoV-2 infected K18-human ACE2 transgenic mice, treatment with SC31 greatly reduced viral loads and attenuated pro-inflammatory responses linked to the severity of COVID-19. Importantly, a comparison of the efficacies of SC31 and its Fc-null LALA variant revealed that the optimal therapeutic efficacy of SC31 requires Fc-mediated effector functions that promote IFNγ-driven anti-viral immune responses, in addition to its neutralization ability. A dose-dependent efficacy of SC31 was observed down to 5mg/kg when administered before viral-induced lung inflammatory responses. In addition, antibody-dependent enhancement was not observed even when infected mice were treated with SC31 at sub-therapeutic doses. In SARS-CoV-2-infected hamsters, SC31 treatment significantly prevented weight loss, reduced viral loads, and attenuated the histopathology of the lungs. In rhesus macaques, the therapeutic potential of SC31 was evidenced through the reduction of viral loads in both upper and lower respiratory tracts to undetectable levels. Together, the results of our preclinical studies demonstrated the therapeutic efficacy of SC31 in three different models and its potential as a COVID-19 therapeutic candidate.

SUBMITTER: Chan CEZ 

PROVIDER: S-EPMC8221499 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.

Chan Conrad E Z CEZ   Seah Shirley G K SGK   Chye De Hoe H   Massey Shane S   Torres Maricela M   Lim Angeline P C APC   Wong Steven K K SKK   Neo Jacklyn J Y JJY   Wong Pui San PS   Lim Jie Hui JH   Loh Gary S L GSL   Wang Dongling D   Boyd-Kirkup Jerome D JD   Guan Siyu S   Thakkar Dipti D   Teo Guo Hui GH   Purushotorman Kiren K   Hutchinson Paul E PE   Young Barnaby E BE   Low Jenny G JG   MacAry Paul A PA   Hentze Hannes H   Prativadibhayankara Venkateshan S VS   Ethirajulu Kantharaj K   Comer Jason E JE   Tseng Chien-Te K CK   Barrett Alan D T ADT   Ingram Piers J PJ   Brasel Trevor T   Hanson Brendon John BJ  

PloS one 20210623 6


Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-19, little is known about their mechanism(s) of action or effective dosing windows. We report the generation and development of SC31, a potent SARS-CoV-2 neutralizing antibody, isolated from a convalescent patient. Antibody-mediated neutralization occurs via an epitope within the receptor-binding domain of the SARS-CoV-2 Spike protein. SC31 exhibited potent anti-SARS-CoV-2 activities in multiple animal models. I  ...[more]

Similar Datasets

| S-EPMC10383564 | biostudies-literature
| S-EPMC7879018 | biostudies-literature
2021-03-01 | GSE161615 | GEO
| S-EPMC5777978 | biostudies-literature
| S-EPMC6781005 | biostudies-literature
| S-EPMC5614562 | biostudies-literature
| S-EPMC4167398 | biostudies-literature
| S-EPMC7022345 | biostudies-literature
| S-EPMC6819135 | biostudies-literature
| S-EPMC10345146 | biostudies-literature